microlyse (TGD001) / TargED - LARVOL DELTA

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial (ASH 2025) - "This effect may contribute to areduction of ischemic thrombus burden and improved clinical outcomes. These findings support theinitiation of an upcoming Phase 1/2 trial in iTTP and selected TMAs, as well as further development inacute ischemic stroke."

First-in-human • P1 data • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Inflammation • Ischemic stroke • Musculoskeletal Diseases • Thrombosis

Novel von willebrand factor targeting thrombolytic TGD001 is effective in diverse thrombotic models, demonstrating its potential as a universal thrombolytic (ASH 2025) - "In both the congenital (Adamts13-/-) and immune-mediated (anti-ADAMTS13 antibody) murine TTP models, TGD001 demonstrated efficacy, with rapidly attenuatedthrombocytopenia and decreased tissue damage within 4 hours in the cTTP model.In conclusion, findings from animal models representing diverse thrombotic and thromboembolicindications demonstrate the therapeutic potential of TGD001 for the treatment of thrombosis. Despitevarying thrombi compositions, TGD001 effectively cleared the macro- and microvasculature, resulting inimproved outcomes and collectively supporting TGD001 as a novel universal thrombolytic."

Cardiovascular • Diabetes • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Pulmonary Embolism • Respiratory Diseases